Skip to main content
. 2018 Jun 14;13(6):e0198768. doi: 10.1371/journal.pone.0198768

Table 1. Baseline characteristics of the study population.

Parameter n = 467
Demographics
Age (years); Median (IQR) 49 (45–53)
Gender; n (%)
      Male 352 (75.4)
HIV risk factors; n (%)
    IDU 226 (48.4)
    Heterosexual relations 91 (19.5)
    MSM 90 (19.3)
    Bisexual relations 7 (1.5)
    Other/Unknown 53 (11.3)
CD4 and HIV viral load
Baseline CD4; median (IQR)
    CD4 count (cells/μL) 580 (372–781)
    CD4% 28 (13)
Nadir CD4; median (IQR) 169 (65–274)
AIDS diagnosis; n (%) 228 (48.8)
Time since HIV diagnosis (years); median (IQR) 17 (10–22)
Years since undetectable viral load (<50 copies/mL); median (IQR) 5.2 (2.2–9.9)
Co-infections; n (%)
    HBV (HbsAg +) 14 (3.0)
    HCV (PCR +) 156 (33.4)
Reasons for switching; n (%)
    Drug toxicity/tolerability 197 (42.2)
    Physician’s criteria* 133 (28.5)
    Unknown reasons 123 (26.3)
    Regimen simplification 38 (8.1)
    Cost reduction————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————-
Multiple reasons (toxicity-physician’s criteria; physician’s criteria-other, simplification-other)
4 (0.9)
28 (6)
Previous cART; n (%)
Single-tablet regimen
    DGV/ABC/3TC 3 (0.6)
    RPV/FTC/TDF 4 (0.9)
    EFV/FTC/TDF 20 (4.3)
Non-nucleoside reverse transcriptase inhibitor**
    RPV 12 (2.6)
    EFV 30 (6.4)
    NVP 18 (3.8)
    ETV 20 (4.3)
Protease inhibitor**
    LPV 38 (8.1)
    FPV 31 (6.6)
    ATV unboosted 65 (13.9)
    ATV boosted 25 (5.3)
    DRV QD 47 (10.1)
    DRV BID 19 (4.07)
Integrase strand inhibitor**
    RAL 118 (25.3)
Nucleoside reverse transcriptase inhibitor
    ABC/3TC 221 (47.3)
    FTC/TDF
AZT/3TC/ABC
124 (26.5)
22 (4.7)
    3TC 36 (7.7)
    ABC 11 (2.3)
    FTC 7 (1.5)
    TDF 8 (1.7)
    AZT
Entry Inhibitors
MVC
21 (4.5)
5 (1.1)
Monotherapy; n (%) 18 (3.8)
    LPV/r 7 (1.5)
    DRV/r 11 (2.3)
Dual therapy**; n (%) 17 (3.6)
    LPV (+3TC: 3; +RAL: 1)
DRV/r (+3TC: 4, +RAL: 3; +ETV: 2; +NVP: 1)
ATV/r (+3TC: 1)
RAL (+DRV/r: 3; +LPV/r: 1; +ETV: 1; +NVP: 1)
Switching to RAL 800 mg QD
4 (0.8)
10 (2.1)
1 (0.2)
6 (1.3)
50 (10.7)

3TC: lamivudine; ABC: abacavir; AIDS: acquired immunodeficiency syndrome; ATV: atazanavir; AZT: zidovudine; cART: combination antiretroviral therapy; DRV: darunavir; DGV: dolutegravir; EFV: efavirenz, ETV: etravirine; HBV: hepatitis B virus; HCV: hepatitis C virus; FPV: fosamprenavir; FTC: emtricitabine; IDU: injection drug use; LPV: lopinavir; MSM: men who have sex with men; MVC: maraviroc; NVP: nevirapine; RPV: rilpivirine; r: ritonavir; TDF: tenofovir; RAL: raltegravir

* Potential drug interactions, better profile, personal decision

**Dual therapy with 3rd agents.